Loading organizations...
§ Private Profile · Cambridge, MA, USA
Biotechnology company developing precision medicines for autoimmune diseases and cancer, leveraging single-cell genomics.
Celsius Therapeutics was a Cambridge, Massachusetts-based biotechnology company that utilized single-cell genomics and computational algorithms to develop precision medicines for autoimmune diseases and oncology. The firm focused on identifying disease-causing cellular interactions to create first-in-class therapies, notably advancing its lead anti-TREM1 antibody for inflammatory bowel disease through Phase 1 clinical trials. Prior to its exit, the biotechnology enterprise raised $148 million in total venture funding, including a $65 million Series A and an $83 million Series B, backed by prominent investors such as Third Rock Ventures, GV, and Casdin Capital. The company also established an oncology partnership with Servier and reached a pre-acquisition valuation of $120 million before being acquired by AbbVie for $250 million in upfront cash. Celsius Therapeutics was founded in 2018 by Aviv Regev, Vijay Kuchroo, Christoph Lengauer, and Ramnik Xavier.
Celsius Therapeutics has raised $148.0M across 2 funding rounds.
Celsius Therapeutics has raised $148.0M in total across 2 funding rounds.
Celsius Therapeutics has raised $148.0M in total across 2 funding rounds.
Celsius Therapeutics's investors include Suzanne Angell, Alexandria Venture Investments, Amgen Ventures, Amplitude Ventures, Catalio Capital Management, Co-win Ventures, Google Ventures, Heritage Provider Network, Section 32, Third Rock Ventures, Alexis A. Borisy, Casdin Capital.
Celsius Therapeutics has raised $148.0M across 2 funding rounds. Most recently, it raised $83.0M Series A Extension in March 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 24, 2022 | $83M Series A Plus | Suzanne Angell | Alexandria Venture Investments, Amgen Ventures, Amplitude Ventures, Catalio Capital, Co WIN Ventures, GV, Heritage Provider Network, Section 32, Third Rock Ventures | Announced |
| May 15, 2018 | $65M Series A | Alexis A. Borisy | Alexandria Venture Investments, Casdin Capital, GV, Heritage Provider Network | Announced |